**Guideline Page and Request**

- **BiNV-20, and BiNV-N**
  - Internal request: Based on FDA approval consider adding ribociclib in combination with letrozole as a treatment option for HER2-negative, metastatic breast cancer.
  - External request: Submission from Novartis Pharmaceuticals, Corp. Consider the use of ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.

**Panel Discussion/References**

Based on the data in the noted reference(s), the panel consensus was to include ribociclib + letrozole as a category 1 option for postmenopausal patients with no prior endocrine therapy within 1 y with the following footnote “Palbociclib or ribociclib in combination with letrozole may be considered in HER2-negative, metastatic breast cancer.”

**Institution Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>0</td>
<td>6</td>
<td>0</td>
</tr>
</tbody>
</table>

[See Submission for references](#)